The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

FRIDAY, June 6, 2025 (HealthDay News) — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

Harrison, who was 21 at the time, showed neither signs nor symptoms related to the virus, and was in a long-term relationship. Young and carefree, Harrison had rarely given her health a second thought ...

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...